First clinical results demonstrate efficacy of VOY-101, a novel gene therapy for GAByOmer Trivizki, MD, MBA,Sydney M Crago,Martin David HarpAugust 18th 2025A 12-month follow-up indicated no dose limiting toxicity and no ocular or systemic adverse effects